Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation

Journal of Cardiology

Volumn 69, Issue 1, 2017, Pages 11-15

  Okishige, Kaoru ^a   Nakamura, Tomofumi ^a   Aoyagi, Hideshi ^a   Kawaguchi, Naohiko ^a   Yamashita, Mitsumi ^a   Kurabayashi, Manabu ^a   Suzuki, Hidetoshi ^a   Asano, Mitsutoshi ^a   Shimura, Tsukasa ^a   Yamauchi, Yasuteru ^a   Sasano, Tetsuo ^b   Hirao, Kenzo ^b  

^a YOKOHAMA CITY MINATO RED CROSS HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Anticoagulant; Atrial fibrillation; Cerebral infarction; Cryoballoon

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; CREATININE; DABIGATRAN; EDOXABAN; HEPARIN; RIVAROXABAN; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

ABLATION CATHETER; ABLATION THERAPY; ADULT; AGED; ANTICOAGULANT THERAPY; AORTOESOPHAGEAL FISTULA; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CATHETER SHEATH; CHADS2 SCORE; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; CRYOABLATION; CRYOBALLOON ABLATION; FEMALE; HEART TAMPONADE; HEMATOMA; HEMOPERICARDIUM; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MAPPING CATHETER; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDIAL EFFUSION; PULMONARY VEIN STENOSIS; RADIOFREQUENCY ABLATION DEVICE; RETROSPECTIVE STUDY; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VASCULAR GUIDE WIRE; ADVERSE EFFECTS; BRAIN; CHEMICALLY INDUCED; CRYOSURGERY; DIAGNOSTIC IMAGING; EMBOLISM; HEMORRHAGE; INCIDENCE; POSTOPERATIVE COMPLICATIONS; PROCEDURES;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN; BRAIN ISCHEMIA; CRYOSURGERY; DABIGATRAN; EMBOLISM; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PYRAZOLES; PYRIDINES; PYRIDONES; RIVAROXABAN; THIAZOLES; WARFARIN;

EID: 84975494349     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2016.04.009     Document Type: Article

References (33)

1. [1] Neumann, T., Vogt, J., Schumacher, B., Dorzewski, A., Kuniss, M., Neuser, H., Kurzidim, K., Berkowitsch, A., Koller, M., Heintze, J., Scholz, U., Wetzel, U., Schneider, M.A.E., Horstkotte, D., Hamm, C.W., et al. Circumferential pulmonary vein isolation with the cryoballoon technique. J Am Coll Cardiol 52 (2008), 273–278.
2. [2] Packer, D.L., Kowal, R.C., Wheelan, K.R., Irwin, J.M., Champagne, J., Guerra, P.G., Dubuc, M., Reddy, V., Nelson, L., Holcomb, R.G., Lehman, J.W., Ruskin, J.N., “Cryoballoon” ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) Pivotal trial. J Am Coll Cardiol 16 (2012), 1713–1723.
3. [3] van Belle, Y., Janse, P., Rivero-Ayerza, M.J., Thornton, A.S., Jessurun, E.R., Theuns, D., Jordaens, L., Pulmonary vein isolation using an occluding cryoballoon for circumferential ablation: feasibility, complication, and short-term outcome. Eur Heart J 28 (2007), 2231–2237.
4. [4] Kondo, T., Miake, J., Kato, M., Ogura, K., Iitsuka, K., Yamamoto, K., Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation. J Cardiol, 2015, 10.1016/j.jjcc.2015.09.012 [Epub ahead of print].
5. [5] Kaseno, K., Naito, S., Nakamura, K., Sakamoto, T., Sasaki, T., Tsukada, N., Hayano, M., Nishiuchi, S., Fuke, E., Miki, Y., Nakamura, K., Tamashita, E., Kumagai, K., Oshima, S., Tada, H., Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 76 (2012), 2337–2342.
6. [6] Lakkireddy, D., Reddy, Y.M., Biase, L.D., Vallakati, A., Mansour, M.C., Santangeli, P., Gangireddy, S., Swarup, V., Chalhoub, F., Atkins, D., Bommana, C.D., Baheiry, S., Ruskin, J.N., Reddy, V., Natale, A., Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation. J Am Coll Cardiol 63 (2014), 982–988.
7. [7] Nagao, T., Inden, Y., Shimano, M., Fujita, M., Yanagisawa, S., Kato, H., Ishikawa, S., Miyoshi, A., Okumura, S., Ohguchi, S., Yamamoto, T., Yoshida, N., Hirai, M., Murohara, T., Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. PACE 38 (2015), 155–163.
8. [8] Giugliano, R., Ruff, C.T., Braunwald, E., Murphy, S.A., Wiviott, S.D., Halperin, J.H., Waldo, A.L., Ezekowitz, M.D., Weitz, J.I., Spinar, J., Ruzyllo, W., Ruda, M., Koretsune, Y., Betcher, J., Shi, M., et al. Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med 369 (2013), 2093–2104.
9. [9] Wardlaw, J.M., Smith, E.E., Biessels, G.J., Cordonnier, C.C., Fazekas, F., Frayne, R., Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12 (2013), 822–838.
10. [10] Snipelisky, D., Ray, J.C., Ung, R., Duart, M., Kaufman, C., Kusumoto, F., A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. J Interv Card Electrophysiol 41 (2014), 231–236.
11. [11] Spragg, D.D., Dalal, D., Cheema, A., Scherr, D., Chilukuri, K., Cheng, A., Henrikson, C.A., Marine, J.E., Berger, R.D., Dong, J., Calkins, H., Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol 19 (2008), 627–631.
12. [12] Dixit, S., Marchlinski, F.E., How to recognize, manage, and prevent complications during atrial fibrillation ablation. Heart Rhythm 4 (2007), 108–115.
13. [13] Gaita, F., Caponi, D., Pianelli, M., Scaglione, M., Toso, E., Cesarani, F., Boffano, C., Gandini, G., Valentini, M.C., De Ponti, R., Halimi, F., Leclercq, J.F., Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 122 (2010), 1667–1673.
14. [14] Takahashi, A., Kuwahara, T., Takahashi, Y., Complications in the catheter ablation of atrial fibrillation: incidence and management. Circ J 73 (2009), 221–226.
15. [15] Sra, J., Atrial fibrillation ablation complications. J Interv Card Electrophysiol 22 (2008), 167–172.
16. [16] Cappato, R., Calkins, H., Chen, S.A., Davies, W., Iesaka, Y., Kalman, J., Kim, Y.H., Klein, G., Natale, A., Packer, D., Skane, A., Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 53 (2009), 1798–1803.
17. [17] Winkle, R.A., Mead, R.H., Engel, G., Kong, M.H., Patrawala, R.A., The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 23 (2012), 264–268.
18. [18] Cappato, R., Calkins, H., Chen, S.A., Davies, W., Iesaka, Y., Kalman, J., Kim, Y.H., Klein, G., Natale, A., Packer, D., Skanes, A., Ambrogi, F., Biganzoli, E., Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3 (2010), 32–38.
19. [19] Sartori, M.T., Imbergamo, S., Zanon, E., Bonaccorso, G., Pittoni, G., Feltracco, P., Ori, C., Pagnan, A., Cella, G., Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center. Clin Appl Thromb Hemost 119 (2009), 121–127.
20. [20] van Ryn, J., Ruehl, D., Priepke, H., Hauel, N., Wienen, W., Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate (Abstract 0370). Haematologica, 93(Suppl. 1), 2008, 148.
21. [21] Mayer, S.A., Brun, N.C., Begtrup, K., Broderick, J., Davis, S., Diringer, M.N., Skolnick, B.E., Steiner, T., FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 358 (2008), 2127–2137.
22. [22] Brody, D.L., Aiyagari, V., Shackelford, A.M., Diringer, M.N., Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2 (2005), 263–267.
23. [23] Di Biase, L., Burkhardt, J.D., Mohanty, P., Sanchez, J., Horton, R., Gallinghouse, G.J., Lakkireddy, D., Verma, A., Khaykin, Y., Hongo, R., Hao, S., Beheiry, S., Penargonio, G., Dello Russo, A., Casella, M., Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 121 (2010), 2550–2556.
24. [24] Di Biase, L., Burkhardt, D., Santangeli, P., Mohanty, P., Sanchez, J., Horton, R., Gallinghouse, G.J., Themistoclakis, S., Rossillo, A., Lakkireddy, D., Reddy, M., Hao, S., Hongo, R., Beheiry, S., Zagrodzky, J., Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the “compare” randomized trial. Circulation 129 (2014), 2638–2644.
25. [25] Vazquez, S.R., Johnson, S.A., Rondina, M.T., Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. Thromb Res 126 (2010), e69–e77.
26. [26] Maddox, W., Kay, G.N., Yamada, T., Osorio, J., Doppalapudi, H., Plumb, V.J., Gunter, A., McElderry, H.T., Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol 24 (2013), 861–865.
27. [27] Lakkireddy, D., Reddy, Y.M., Di Biase, L., Vallakati, A., Mansour, M.C., Santangeli, P., Gangireddy, S., Swarup, V., Chalhoub, F., Atkins, D., Bommana, S., Verma, A., Sanchez, J.E., Burkhardt, J.D., Barrett, C.D., Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 63 (2014), 982–988.
28. [28] Hermans, C., Claeys, D., Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin 22 (2006), 471–481.
29. [29] Granger, C.B., Miller, J.M., Bovill, E.G., Gruber, A., Tracy, R.P., Krucoff, M.W., Green, C., Berrios, E., Harrington, R.A., Ohman, E.M., Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 91 (1995), 1929–1935.
30. [30] Lee, D.S., Dorian, P., Downar, E., Burns, M., Yeo, E.L., Gold, W.L., Paquette, M., Lau, W., Newman, D.M., Thrombogenicity of radiofrequency ablation procedures: what factors influence thrombin generation?. Europace 3 (2001), 195–200.
31. [31] Hussein, A.A., Martin, D.O., Saliba, W., Patel, D., Karim, S., Batal, O., Banna, M., Williams-Andrews, M., Sherman, M., Kanj, M., Bhargava, M., Dresing, T., Callahan, T., Tchou, P., Di Biase, L., Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 6 (2009), 1425–1429.
32. [32] Hakalahti, A., Uusimaa, P., Ylitalo, K., Raatikainen, M.J., Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. Europace 13 (2011), 640–645.
33. [33] Winkle, R.A., Mead, R.H., Engel, G., Kong, M.H., Patrawala, R.A., The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 22 (2012), 948–955.